Program
sacubitril
Also written as “sacubitril/valsartan”, “Experimental: Sacubitril/Allisartan and Amlodipine Group” and “AHU377”.
Its studies are mostly in Heart Failure · Essential Hypertension · Chagas Disease · Myocardial Infarction · Isolated Systolic Hypertension, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 80 open or running | phase 4since Jul 10, 2019 | Oct 5, 2007 | none ahead |
| Shenzhen Salubris Pharmaceuticals | 20 open or running | phase 3since Jul 9, 2026 | Jul 9, 2026 | none ahead |
| Viatris | 22 open or running | phase 1since Jan 25, 2024 | Jan 25, 2024 | none ahead |
| Dr. Reddy's Laboratories | 11 open or running | phase 1since Dec 12, 2023 | Dec 12, 2023 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 5, 2007First study: phase 2 study in HypertensionNew to NovartisNovartis · NCT00549770 · 1,334 enrolled · United States, Argentina, Canada and more
- Jan 20, 2011Phase 2 study in Isolated Systolic HypertensionNovartis · NCT01281306 · 910 enrolled · United States, Argentina, Canada and more
- Feb 23, 2017Phase 3 study in Cardiovascular DiseasesNovartis · NCT03066804 · 2,572 enrolled · United States, Argentina, Austria and more
- Dec 20, 2018Phase 3 study in Heart FailureNovartis · NCT03785405 · 216 enrolled · United States, Argentina, Austria and more
- Jun 13, 2019Phase 3 study in Heart Failure With Preserved Ejection Fraction (HFpEF)Novartis · NCT03988634 · 467 enrolled · United States, Canada
- Jul 10, 2019Phase 4 study in Chagas DiseaseNovartis · NCT04023227 · 922 enrolled · Argentina, Brazil, Colombia and more
- Nov 4, 2020Phase 3 study in Post Myocardial InfarctionNovartis · NCT04637555
- Nov 13, 2023Phase 3 study in Heart FailureNovartis · NCT06149104 · 8 enrolled · Japan
- Dec 12, 2023Dr. Reddy's Laboratories's first study: phase 1 study in Healthy VolunteersNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT06193187 · 48 planned · Thailand
- Jan 25, 2024Viatris's first study: phase 1 study in Chronic Heart FailureNew to ViatrisViatris · NCT06266988 · 48 planned
- Feb 14, 2024Phase 1 study in Bioequivalence StudyViatris · NCT06273254 · 48 planned · Thailand
- Jul 9, 2026Shenzhen Salubris Pharmaceuticals's first studies: 2 phase 3 studies in Essential HypertensionNew to Shenzhen Salubris PharmaceuticalsShenzhen Salubris Pharmaceuticals · NCT07704697, NCT07704684
TargetBeta
“A neprilysn (NEP) inhibitor prodrug with natriuretic activity”NCIt, by rule
“Neprilysin inhibitor”ChEMBL 37, by rule
Studies
All 13 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07704697Essential Hypertension · China | 3 | Completed | Shenzhen Salubris Pharmaceuticals | Nov 10, 2025 | 346 |
| NCT07704684Essential Hypertension · China | 3 | Completed | Shenzhen Salubris Pharmaceuticals | Aug 26, 2025 | 376 |
| NCT06273254Bioequivalence Study · Thailand | 1 | Not yet recruiting | Viatris | May 2024 | 48 |
| NCT06266988Chronic Heart Failure | 1 | Not yet recruiting | Viatris | Apr 2024 | 48 |
| NCT06193187Healthy Volunteers · Thailand | 1 | Not yet recruiting | Dr. Reddy's Laboratories | Mar 2024 | 48 |
| NCT06149104Heart Failure · Japan | 3 | Completed | Novartis | Aug 14, 2024 | 8 |
| NCT04637555Post Myocardial Infarction | 3 | Withdrawn | Novartis | Jun 1, 2023 | 0 |
| NCT04023227Chagas Disease · Argentina, Brazil, Colombia and more | 4 | Completed | Novartis | Mar 16, 2025 | 922 |
| NCT03988634Heart Failure With Preserved Ejection Fraction (HFpEF) · United States, Canada | 3 | Completed | Novartis | Dec 14, 2022 | 467 |
| NCT03785405Heart Failure · United States, Argentina, Austria and more | 3 | Completed | Novartis | Dec 29, 2023 | 216 |
| NCT03066804Cardiovascular Diseases · United States, Argentina, Austria and more | 3 | Completed | Novartis | Oct 28, 2019 | 2,572 |
| NCT01281306Isolated Systolic Hypertension · United States, Argentina, Canada and more | 2 | Completed | Novartis | Dec 2011 | 910 |
| NCT00549770Hypertension · United States, Argentina, Canada and more | 2 | Completed | Novartis | Jul 2008 | 1,334 |
How it is read
Names in the registry
- “sacubitril/valsartan”, 5 entries
- “Experimental: Sacubitril/Allisartan and Amlodipine Group”, 2 entries
- “AHU377”, 2 entries
- “Sacubitril/valsartan”, 1 entry
- “Sacubitril and Valsartan Tablets 49mg/51mg”, 1 entry
Conditions, from the studies’ own filings
- Heart Failure, 5 studies
- Essential Hypertension, 2 studies
- Chagas Disease, 1 study
- Myocardial Infarction, 1 study
- Isolated Systolic Hypertension, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.